We leverage our experience in biopharmaceuticals and small molecules to develop, scale-up and optimize processes for Antibody-Drug Conjugates (ADCs) in support of both clinical and commercial manufacturing processes.

By leveraging our experience in biopharmaceuticals and small molecule drug process development and scale-up, we can manufacture high potency ADCs to support both clinical development and commercial manufacture of Antibody-Drug Conjugates (ADCs). 

Unlike other contract development and manufacturing organizations (CDMOs) in the industry, we are in the unique position to offer:

  • Complete development, optimization and manufacturing services for mammalian and microbial derived targeting agents
  • Chemical synthesis of linkers and payloads
  • Advanced conjugation technologies, process development, process optimization and BLA activities
  • Formulation development (liquid and lyophilized) and drug product development
  • Regulatory consulting and submission writing

We have experience with a wide range of bioconjugation technologies including the synergistic pooling of large and small molecule manufacturing practices to achieve delivery. We can provide a tailored solution for you to minimize risk, time cost and supply chain complexity.

Development offering by phase

We have 10 years of milestones in ADC development and manufacture. Contact us to find out how we can support your development program.

Related Content

Our GS Gene Expression System® has options to engineer and express conjugation-competent antibodies. Applications include antibody drug conjugates (ADCs), half-life extension and imaging.

Unlike other contract development and manufacturing organizations(CDMOs), we are in the unique position to offer complete development and manufacturing services from both mammalian cell culture and advanced chemical synthesis for the production of Antibody-Drug Conjugates (ADCs). From process development to manufacturing scale-up, we are proud to offer more ways than ever to deliver your product.